Archive · 25 Aug 2026
Sai Parenterals Expands Australian OTC Supply Commitments to ₹1,506 Crore
Sai Parenterals supplies over-the-counter medicines in Australia.
It has renewed one of its supply contracts for three more years.
The new deal is worth AU$30 million.
This brings its total Australian supply commitments to AU$232 million.
That amount is about ₹1,506 crore.
The company had signed a larger AU$202 million agreement in July.
Sai Parenterals wants to move production from outside manufacturers to its own factories.
This could give the company a larger role in making the products it supplies.
Sai Parenterals signed a fresh AU$30 million, three-year Australian OTC supply agreement.
The renewal raises the company’s total contracted OTC commitments in Australia to AU$232 million.
The combined commitments are valued at approximately ₹1,506 crore.
The latest agreement follows a larger AU$202 million contract signed in July.
Sai Parenterals plans to shift production from third-party manufacturers to its own facilities.
- Who
- Sai Parenterals and its Australian OTC supply partner, which is not named in the article.
- What
- A new AU$30 million, three-year supply agreement was signed, raising total Australian OTC commitments to AU$232 million.
- When
- The latest agreement follows a larger AU$202 million agreement signed in July.
- Where
- Australia.
- Why
- Sai Parenterals is strengthening its Australian OTC business and looking to shift production from third-party manufacturers to its own facilities.
- Latest agreement
- AU$30 million
- Agreement duration
- Three years
- Total Australian commitments
- AU$232 million
- Approximate rupee value
- ₹1,506 crore
- Earlier agreement
- AU$202 million, signed in July
- Production strategy
- Shift production from third-party manufacturers to Sai Parenterals’ own facilities